Prognosis and Outcome of Cerebral Sinus Venous Thrombosis—A Multicenter Cohort Study
Table 1
Comparison of CSVT patients, Survival and Mortality.
Characteristics
Mortality
Survival
Age, mean (SD)
59.8 (17.7)
40.9 (18.0)
<0.001
Gender male (%)
8 (38)
161 (33)
0.707
Smoking (%)
3 (14)
89 (18)
0.582
Hyperlipidemia (%)
4 (19)
13 (3)
0.219
Hypertension (%)
6 (29)
40 (8)
0.006
Obesity (%)
0 (0)
21 (4)
0.273
Diabetes (%)
3 (14)
27 (6)
0.178
Malignancy (%)
17 (81)
61 (13)
<0.001
Previous thrombotic events (%)
0 (0)
40 (8)
0.163
Oral contraceptives (%)
0 (0)
106 (22)
0.013
Precipitating triggers
Dehydration (%)
0 (0)
12 (2)
0.761
Infections (%)
1 (5)
29 (6)
0.802
Clinical presentation
Papilledema (%)
3 (14)
122 (25)
0.299
Headache (%)
9 (43)
361 (74)
<0.001
Vomiting (%)
2 (10)
77 (15)
0.386
Seizure (%)
3 (14)
99 (20)
0.459
Any focal neurological deficit (%)
11 (52)
121 (24)
0.029
NIHSS upon admission (IQR)
1 (0-12)
0 (0-0)
<0.001
Hematological workup
APLA (%)
1 (5)
60 (12)
0.275
Protein C/S deficiency (%)
1 (5)
18 (4)
0.963
Factor V deficiency (%)
0 (0)
37 (8)
0.182
Factor II mutation (%)
0 (0)
9 (2)
0.522
PT 20210
0 (0)
25 (5)
0.277
Behcet’s disease (%)
0 (0)
18 (4)
0.364
MTHFR (%)
0 (0)
24 (5)
0.283
JAK 2 (%)
0 (0)
33 (7)
0.223
Thrombocytosis (%)
0 (0)
25 (5)
0.200
Hyperhomocysteinemia (%)
0 (0)
9 (2)
0.526
Any coagulopathy (%)
1 (5)
193 (40)
<0.001
Radiological findings
Multiple veins (%)
8 (38)
117 (24)
0.132
Cortical vein involvement (%)
2 (10)
54 (11)
0.828
Deep vein involvement (%)
3 (14)
20 (4)
0.027
Venous infarction (%)
6 (29)
43 (9)
0.012
ICH (%)
6 (29)
78 (16)
0.154
Involved sinus (%)
Isolated SSS
10 (48)
178 (36)
0.289
Transverse sinus
11 (52)
323 (66)
0.171
Sigmoid sinus
10 (48)
312 (64)
0.116
Cavernous sinus
2 (10)
8 (2)
0.011
NIHSS: National Institute of Health Stroke Scale, APLA: antiphospholipid antibodies, PT 20210: prothrombin 20210, MTHFR: methylenetetrahydrofolate reductase, ICH: intracerebral hemorrhage, SSS: superior sagittal sinus.
